Related Experiment Video
Updated: Aug 2, 2025
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
IL1R2 is a Novel Prognostic Biomarker for Lung Adenocarcinoma
Ying Zhang1,2, Danyu Ma1, Yile Gong3
1Departments of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, P.R. China.
Aims:
The aim of this study is to figure out the role of IL1R2 in LUAD (lung adenocarcinoma).
Background:
IL1R2, a special member of IL-1 receptor family, binds to IL-1 and plays an important role in inhibiting IL-1 pathway, which seems to be involved in tumorigenesis. Emerging studies demonstrated higher IL1R2 expression levels in several malignancies.
Objective:
In the present study, we assessed the expression of IL1R2 in LUAD tissues with immunohistochemistry and explored various databases to determine whether it could be a potential prognostic biomarker and therapeutic target.
Methods:
The expression level of IL1R2 in lung adenocarcinoma was analyzed by Immunohistochemistry and UALCAN database. The correlation between IL1R2 expression and the patient prognosis was identified by Kaplan-Meier plotter. The correlation of IL1R2 expression with immune infiltrates was clarified by TIMER database. The protein-protein interaction network and gene functional enrichment analysis were constructed and performed by STRING and Metascape database.
Results:
Immunohistochemistry showed that the expression of IL1R2 was higher in tumor tissues of LUAD patients and that patients with lower IL1R2 level have a better prognosis than their counterparts. We validated our findings in several online databases and found that IL1R2 gene was also positively correlated with B cells and neutrophils and biomarkers of CD8+T cells and exhausted T cells. PPI network and gene enrichment analyses showed that expression of IL1R2 was also associated with complex functionspecific networks involving IL-1 signal, NF-KappaB transcription factors.
Conclusion:
According to these findings, we demonstrated that IL1R2 was involved in the progression and prognosis of LUAD and the underlying mechanism needs further investigation.
Insights
Interleukin-1 receptor 2 (IL1R2) is upregulated in lung adenocarcinoma (LUAD) and associated with poorer patient prognosis. Targeting IL1R2 may offer new therapeutic strategies for LUAD.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Interleukin-1 receptor 2 (IL1R2) is part of the IL-1 receptor family and regulates the IL-1 pathway, implicated in tumorigenesis.
- Elevated IL1R2 expression has been observed in various cancers, suggesting a potential role in malignancy.
Purpose of the Study:
- To investigate the role of IL1R2 in lung adenocarcinoma (LUAD).
- To evaluate IL1R2 as a prognostic biomarker and potential therapeutic target in LUAD.
Main Methods:
- Immunohistochemistry was used to assess IL1R2 expression in LUAD tissues.
- Bioinformatic analyses utilized UALCAN, Kaplan-Meier plotter, TIMER, STRING, and Metascape databases.
- Correlations between IL1R2 expression, patient prognosis, and immune infiltrates were analyzed.
Main Results:
- IL1R2 expression was significantly higher in LUAD tumor tissues compared to normal tissues.
- Lower IL1R2 levels correlated with better patient prognosis.
- IL1R2 expression showed positive correlations with B cells, neutrophils, CD8+ T cells, and exhausted T cells.
- Functional analyses linked IL1R2 to IL-1 signaling and NF-KappaB pathways.
Conclusions:
- IL1R2 plays a role in the progression and prognosis of LUAD.
- Further research is needed to elucidate the underlying mechanisms of IL1R2 in LUAD.
